# Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

> **NCT06675864** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (estimated)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** rapcabtagene autoleucel (YTB323)

## Key facts

- **NCT ID:** NCT06675864
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2030-06-14
- **Final completion:** 2030-06-14
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675864, "Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06675864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*